Sleep Disorders are a Prevalent and Serious Comorbidity in Dry Eye.
Masahiko Ayaki, Kazuo Tsubota, Motoko Kawashima, Taishiro Kishimoto, Masaru Mimura, Kazuno Negishi
Summary
Possible explanations for sleep disorders in DED may be depression, pain, and eye exposure at night.
Abstract
PURPOSE
Sleep is an essential life habit and closely associated with lifespan, diabetes, hypertension, and mental health. Sleep disorders are a prominent, but overlooked problem in patients with dry eye disease (DED), characterized by a poor sleep index, short sleep duration, long sleep latency, and poor subjective sleep. DED and sleep disorders are more prevalent in women than men. Moreover, sleep quality in DED is worse than in other eye diseases, including glaucoma, retinal diseases, cataract, and allergic and chronic conjunctivitis.
METHODS
We reviewed the literature for studies investigating sleep and health, eyes and sleep, and DED and sleep, in terms of systemic and eye health, especially in women.
RESULTS
Two studies reported that approximately half of patients with DED suffer from poor sleep. The severity of mood disorders, including anxiety and depression, is correlated strongly with sleep disorders in DED, and the symptoms and signs of DED, especially pain, also are correlated with sleep quality. Sleep disorders are documented in primary Sjögren's syndrome and an association with sleep apnea and depression is suggested. Primary Sjögren's syndrome includes arthritis and other rheumatic disease causing pain and fatigue; however, how sicca contributes to sleep disorders is not known.
CONCLUSIONS
Possible explanations for sleep disorders in DED may be depression, pain, and eye exposure at night. Reciprocal effects may be expected and consultation-liaison psychiatry is recommended for the management of sleep disorders in DED. Topical medication and lid heating also may be advantageous for sleep quality in DED.
More by Masahiko Ayaki
View full profile →Symptomatic Presbyopia may Develop Earlier in Patients With Glaucoma-A Cross-Sectional Retrospective Cohort Study.
Presbyopia Progression From the Age of 40 to 79 Years in Glaucoma Patients Treated With Prostaglandin F Receptor Agonists.
Top Research in Quality of Life
Browse all →Neuroprotective strategies for retinal disease.
Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.
The Association Between Glaucoma, Anxiety, and Depression in a Large Population.
Discussion
Comments and discussion will appear here in a future update.